Index RUT
P/E -
EPS (ttm) -2.92
Insider Own 7.86%
Shs Outstand 24.14M
Perf Week 2.71%
Market Cap 4.38B
Forward P/E 26.05
EPS next Y 6.88
Insider Trans -2.80%
Shs Float 22.51M
Perf Month 11.17%
Income -70.79M
PEG -
EPS next Q 1.24
Inst Own 98.10%
Short Float 3.69%
Perf Quarter 46.92%
Sales 2.30B
P/S 1.90
EPS this Y -22.99%
Inst Trans 5.35%
Short Ratio 2.83
Perf Half Y 76.22%
Book/sh 83.43
P/B 2.15
EPS next Y 32.12%
ROA -1.62%
Short Interest 0.83M
Perf Year 51.20%
Cash/sh 12.39
P/C 14.47
EPS next 5Y 16.00%
ROE -3.41%
52W Range 78.28 - 188.53
Perf YTD 79.67%
Dividend Est. -
P/FCF 26.15
EPS past 5Y -
ROI -1.94%
52W High -4.95%
Beta 0.66
Dividend TTM -
Quick Ratio 1.07
Sales past 5Y 13.31%
Gross Margin 31.60%
52W Low 128.92%
ATR (14) 5.56
Dividend Ex-Date -
Current Ratio 2.40
EPS Y/Y TTM -44.34%
Oper. Margin 0.80%
RSI (14) 61.36
Volatility 3.19% 3.15%
Employees 14000
Debt/Eq 0.82
Sales Y/Y TTM 0.27%
Profit Margin -3.07%
Recom 1.83
Target Price 162.00
Option/Short Yes / Yes
LT Debt/Eq 0.79
EPS Q/Q -112.70%
Payout -
Rel Volume 0.92
Prev Close 176.92
Sales Surprise 4.38%
EPS Surprise 56.31%
Sales Q/Q 8.56%
Earnings Aug 07 AMC
Avg Volume 293.37K
Price 179.20
SMA20 2.33%
SMA50 13.19%
SMA200 51.88%
Trades
Volume 268,478
Change 1.29%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-21-24 Initiated
Needham
Hold
Jun-17-24 Upgrade
Raymond James
Mkt Perform → Outperform
$135
Nov-08-22 Downgrade
Raymond James
Outperform → Mkt Perform
Mar-31-20 Upgrade
CJS Securities
Market Perform → Market Outperform
Mar-18-20 Upgrade
KeyBanc Capital Markets
Sector Weight → Overweight
$206
Aug-08-19 Downgrade
Raymond James
Strong Buy → Outperform
Oct-17-17 Initiated
KeyBanc Capital Mkts
Sector Weight
Jun-20-17 Downgrade
Sidoti
Buy → Neutral
Mar-11-16 Initiated
Gabelli & Co
Buy
$128
Nov-06-15 Reiterated
ROTH Capital
Buy
$124 → $130
Aug-11-15 Reiterated
ROTH Capital
Buy
$102 → $124
May-06-15 Reiterated
ROTH Capital
Buy
$96 → $102
Feb-10-15 Reiterated
ROTH Capital
Buy
$82 → $96
Nov-11-14 Upgrade
ROTH Capital
Neutral → Buy
$56 → $82
May-09-13 Downgrade
The Benchmark Company
Buy → Hold
Sep-27-12 Reiterated
The Benchmark Company
Buy
$60 → $69
Apr-12-12 Initiated
The Benchmark Company
Buy
$60
Sep-26-11 Reiterated
Ticonderoga
Buy
$52 → $49
Oct-29-09 Initiated
C.K. Cooper
Buy
$45
Oct-08-09 Initiated
Roth Capital
Hold
$40
Show Previous Ratings
Sep-19-24 12:20PM
Sep-17-24 09:15AM
Sep-16-24 10:34AM
Sep-10-24 06:11AM
Aug-23-24 09:15AM
09:40AM
Loading…
Aug-22-24 09:40AM
Aug-21-24 08:30AM
Aug-12-24 07:13AM
Aug-09-24 06:28AM
Aug-08-24 07:45PM
(Morningstar Research) +24.27%
Aug-07-24 06:15PM
05:08PM
(Associated Press Finance)
04:05PM
Jul-26-24 06:40PM
Jul-24-24 08:30AM
07:42AM
Loading…
Jul-23-24 07:42AM
Jun-17-24 09:00AM
May-31-24 02:44AM
May-08-24 02:43PM
11:00AM
06:27AM
03:44AM
May-07-24 09:01PM
05:55PM
05:55PM
04:52PM
(Associated Press Finance)
04:05PM
Apr-23-24 08:30AM
Mar-13-24 08:30AM
Mar-05-24 11:41PM
05:15PM
Loading…
Mar-01-24 05:15PM
Feb-28-24 07:48PM
(Morningstar Research) +5.31%
09:49AM
09:36AM
(Thomson Reuters StreetEvents)
Feb-27-24 06:20PM
05:21PM
(Associated Press Finance)
04:36PM
04:05PM
Feb-20-24 10:00AM
Feb-14-24 11:18PM
Feb-13-24 09:02AM
08:30AM
Nov-27-23 06:28PM
Nov-07-23 10:36AM
Nov-06-23 11:37PM
05:23PM
05:17PM
(Associated Press Finance)
04:05PM
Oct-27-23 09:06PM
Oct-23-23 08:30AM
Sep-25-23 08:40AM
Sep-12-23 01:01AM
Sep-05-23 08:30AM
Sep-04-23 09:34AM
Aug-29-23 08:00AM
Aug-09-23 07:01AM
Aug-08-23 07:36PM
(Morningstar Research) -16.59%
06:31AM
(Thomson Reuters StreetEvents)
Aug-07-23 08:13PM
06:40PM
05:31PM
04:05PM
Jul-24-23 08:30AM
Jun-21-23 08:00PM
Jun-20-23 05:13PM
May-10-23 06:09AM
May-09-23 05:25PM
(Morningstar Research) +13.64%
05:57AM
(Thomson Reuters StreetEvents)
May-08-23 05:35PM
04:29PM
04:05PM
Apr-26-23 08:00PM
Apr-24-23 07:56PM
08:30AM
Apr-11-23 07:07AM
Mar-29-23 09:47AM
Mar-15-23 05:55PM
Mar-09-23 08:30AM
Mar-02-23 05:44AM
Mar-01-23 07:11PM
05:15AM
Feb-28-23 11:05AM
06:31AM
(Thomson Reuters StreetEvents)
Feb-27-23 06:15PM
04:05PM
Feb-26-23 08:04AM
Feb-21-23 08:30AM
Feb-13-23 08:30AM
Feb-08-23 08:00AM
Jan-23-23 08:55AM
Jan-20-23 07:21PM
(Morningstar Research) +5.83%
Dec-19-22 08:30AM
Dec-03-22 07:28AM
Nov-07-22 06:35PM
04:05PM
Nov-06-22 07:21AM
Nov-01-22 09:00AM
Oct-31-22 04:01PM
Oct-07-22 10:08AM
Oct-06-22 08:30AM
ICU Medical, Inc. develops, manufactures, and sells innovative medical products used in infusion therapy and critical care applications. Its product portfolio includes IV smart pumps, sets, connectors, closed system transfer devices for hazardous drugs, sterile IV solutions, cardiac monitoring systems, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Jain Vivek Chairman and CEO Oct 01 '24 Option Exercise 88.76 12,000 1,065,120 116,593 Oct 01 05:16 PM Jain Vivek Chairman and CEO Oct 01 '24 Sale 178.46 12,000 2,141,580 104,593 Oct 01 05:16 PM VIVEK JAIN Officer Oct 01 '24 Proposed Sale 178.46 12,000 2,141,579 Oct 01 04:23 PM Jain Vivek Chairman and CEO Sep 03 '24 Option Exercise 88.76 12,000 1,065,120 109,033 Sep 03 06:05 PM Jain Vivek Chairman and CEO Sep 03 '24 Sale 163.46 12,000 1,961,540 104,593 Sep 03 06:05 PM VIVEK JAIN Officer Sep 03 '24 Proposed Sale 163.46 12,000 1,961,539 Sep 03 04:27 PM Woolson Daniel VP, GM-Infusion Capital Aug 30 '24 Sale 163.22 2,502 408,370 13,107 Aug 30 05:26 PM Woolson Daniel Officer Aug 30 '24 Proposed Sale 163.99 2,502 410,303 Aug 30 05:10 PM Jain Vivek Chairman and CEO Aug 16 '24 Option Exercise 88.76 12,000 1,065,120 116,593 Aug 16 05:22 PM Jain Vivek Chairman and CEO Aug 16 '24 Sale 156.04 12,000 1,872,480 104,593 Aug 16 05:22 PM VIVEK JAIN Officer Aug 16 '24 Proposed Sale 156.04 12,000 1,872,480 Aug 16 04:36 PM Smiths Group International Hol Other Aug 13 '24 Proposed Sale 143.90 415,771 59,829,447 Aug 13 04:09 PM Sanzone Virginia Ruth VP, General Counsel Aug 08 '24 Sale 144.11 2,050 295,426 4,482 Aug 08 04:56 PM VIRGINIA SANZONE Officer Aug 08 '24 Proposed Sale 144.11 2,050 295,426 Aug 08 04:11 PM Voigtlander Christian B. Chief Operating Officer May 30 '24 Sale 103.95 12,539 1,303,485 0 May 30 06:03 PM FINNEY ELISHA W Director May 16 '24 Sale 104.95 300 31,484 2,129 May 16 07:30 PM Hoffmeister David F Director May 15 '24 Option Exercise 0.00 948 0 3,027 May 15 06:17 PM KENNEDY KOLLEEN T Director May 15 '24 Option Exercise 0.00 948 0 1,562 May 15 06:14 PM Abbey Donald Director May 15 '24 Option Exercise 0.00 948 0 3,027 May 15 06:10 PM FINNEY ELISHA W Director May 15 '24 Option Exercise 0.00 948 0 2,429 May 15 06:06 PM Greenberg David C. Director May 15 '24 Option Exercise 0.00 948 0 5,037 May 15 05:53 PM Hernandez Laurie Director May 15 '24 Option Exercise 0.00 948 0 1,885 May 15 05:49 PM Sousa Ben Chief Information Officer May 10 '24 Sale 105.55 2,000 211,090 1,319 May 10 01:31 PM Voigtlander Christian B. Chief Operating Officer Mar 15 '24 Option Exercise 0.00 3,247 0 14,319 Mar 18 04:51 PM Woolson Daniel VP, GM-Infusion Capital Mar 15 '24 Option Exercise 0.00 2,923 0 16,903 Mar 18 04:49 PM Sousa Ben Chief Information Officer Mar 15 '24 Option Exercise 0.00 1,299 0 3,782 Mar 18 04:46 PM Sanzone Virginia Ruth VP, General Counsel Mar 15 '24 Option Exercise 0.00 1,624 0 7,422 Mar 18 04:44 PM Jain Vivek Chairman and CEO Mar 15 '24 Option Exercise 0.00 4,871 0 107,264 Mar 18 04:38 PM Bonnell Brian Michael Chief Financial Officer Mar 15 '24 Option Exercise 0.00 3,247 0 26,734 Mar 18 04:35 PM Woolson Daniel VP, GM-Infusion Capital Mar 15 '24 Sale 98.27 791 77,733 13,980 Mar 15 05:24 PM LOPEZ GEORGE A Director Mar 14 '24 Sale 101.87 7,978 812,741 877,343 Mar 14 06:13 PM LOPEZ GEORGE A Director Mar 11 '24 Sale 104.22 1,890 196,968 317,753 Mar 13 04:09 PM LOPEZ GEORGE A Director Mar 12 '24 Sale 101.51 1,522 154,497 316,231 Mar 13 04:09 PM Woolson Daniel VP, GM-Infusion Capital Mar 08 '24 Option Exercise 0.00 2,020 0 15,665 Mar 11 04:35 PM Woolson Daniel VP, GM-Infusion Capital Mar 07 '24 Option Exercise 0.00 6,758 0 16,209 Mar 11 04:35 PM Sousa Ben Chief Information Officer Mar 08 '24 Option Exercise 0.00 674 0 2,723 Mar 11 04:33 PM Sousa Ben Chief Information Officer Mar 07 '24 Option Exercise 0.00 3,003 0 2,967 Mar 11 04:33 PM Voigtlander Christian B. Chief Operating Officer Mar 08 '24 Option Exercise 0.00 9,499 0 15,070 Mar 11 04:32 PM Voigtlander Christian B. Chief Operating Officer Mar 07 '24 Option Exercise 0.00 15,017 0 13,842 Mar 11 04:32 PM Bonnell Brian Michael Chief Financial Officer Mar 08 '24 Option Exercise 0.00 9,499 0 27,485 Mar 11 04:28 PM Bonnell Brian Michael Chief Financial Officer Mar 07 '24 Option Exercise 0.00 15,017 0 26,257 Mar 11 04:28 PM Jain Vivek Chairman and CEO Mar 08 '24 Option Exercise 0.00 10,856 0 106,962 Mar 11 04:26 PM Jain Vivek Chairman and CEO Mar 07 '24 Option Exercise 0.00 22,524 0 108,078 Mar 11 04:26 PM Sanzone Virginia Ruth VP, General Counsel Mar 08 '24 Option Exercise 0.00 2,273 0 7,044 Mar 11 04:24 PM Sanzone Virginia Ruth VP, General Counsel Mar 07 '24 Option Exercise 0.00 7,509 0 11,600 Mar 11 04:24 PM Sanzone Virginia Ruth VP, General Counsel Mar 08 '24 Sale 104.57 3,300 345,088 4,771 Mar 11 04:24 PM LOPEZ GEORGE A Director Mar 07 '24 Sale 105.77 18,954 2,004,708 335,015 Mar 11 04:22 PM LOPEZ GEORGE A Director Mar 08 '24 Sale 105.94 15,372 1,628,454 319,643 Mar 11 04:22 PM LOPEZ GEORGE A Director Mar 04 '24 Sale 106.79 7,051 752,993 353,969 Mar 11 04:22 PM Voigtlander Christian B. Chief Operating Officer Mar 04 '24 Sale 107.19 13,603 1,458,090 0 Mar 05 01:42 PM SMITHS GROUP PLC Former 10% Owner Feb 29 '24 Sale 106.08 830,000 88,042,250 1,670,000 Mar 01 04:16 PM Smiths Group International Hol Former 10% Owner Feb 29 '24 Sale 106.08 830,000 88,042,250 1,670,000 Mar 01 04:16 PM Jain Vivek Chairman and CEO Feb 12 '24 Option Exercise 58.79 146,366 8,604,857 170,043 Feb 14 04:23 PM Jain Vivek Chairman and CEO Feb 12 '24 Option Exercise 58.79 66,000 3,880,140 126,000 Feb 14 04:23 PM Woolson Daniel VP, GM-Infusion Capital Dec 01 '23 Sale 88.03 1,729 152,196 9,877 Dec 01 05:08 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite